SELLAS Life Sciences Group Inc (NAS:SLS)
$ 0.98 -0.03 (-2.97%) Market Cap: 68.97 Mil Enterprise Value: 50.63 Mil PE Ratio: 0 PB Ratio: 3.92 GF Score: 39/100

Sellas Life Sciences Group Inc Corporate Analyst Meeting Transcript

Nov 15, 2019 / 01:15PM GMT
Release Date Price: $5.15 (-16.53%)
Angelos M. Stergiou
SELLAS Life Sciences Group, Inc. - Founder, Vice Chairman, President & CEO

Well, good morning, everyone. I'm Angelos Stergiou, President and CEO of SELLAS. And a very warm welcome to our first R&D event. It's really an honor to be here today, and I'm very happy to see so many familiar faces, actually. And -- in the audience, and for those of us joining us via webcast, thanks for joining in. Firstly, I would like to thank our shareholders for their continued support. The Board and management are committed to the goal to create value for our shareholders and to develop life-saving drugs. We're very pleased to host because we had to share some exciting information and data around SELLAS' lead assets and program around galinpepimut-S or GPS in short. And so I'm just going to cut right to it. But first, we're going to be making forward-looking statements today, so please refer to the filing on our website to remind yourself of the risk factors.

Today, we hope to convey a theme really of growth and transformation since SELLAS started trading on NASDAQ last year, and we're

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot